Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

被引：0
|
作者：
C Kahlert
H Weber
C Mogler
F Bergmann
P Schirmacher
H G Kenngott
U Matterne
N Mollberg
N N Rahbari
U Hinz
M Koch
M Aigner
J Weitz
机构：
[1] University of Heidelberg,Department of Surgery
[2] Im Neuenheimer Feld 110,undefined
[3] Institute of Pathology,undefined
[4] University of Heidelberg,undefined
[5] Im Neuenheimer Feld 110,undefined
[6] Institute of Occupational and Social medicine,undefined
[7] Voßstrasse 2,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
ALCAM; CD166; ADAM17/TACE; pancreatic cancer; prognostic marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 464
页数：7
相关论文
共 50 条
  • [1] Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
    Kahlert, C.
    Weber, H.
    Mogler, C.
    Bergmann, F.
    Schirmacher, P.
    Kenngott, H. G.
    Matterne, U.
    Mollberg, N.
    Rahbari, N. N.
    Hinz, U.
    Koch, M.
    Aigner, M.
    Weitz, J.
    BRITISH JOURNAL OF CANCER, 2009, 101 (03) : 457 - 464
  • [2] ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer
    Tachezy, Michael
    Zander, Hilke
    Marx, Andreas H.
    Stahl, Phillip R.
    Gebauer, Florian
    Izbicki, Jakob R.
    Bockhorn, Maximilian
    PLOS ONE, 2012, 7 (06):
  • [3] ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients
    Tachezy, Michael
    Effenberger, Katharina
    Zander, Hilke
    Minner, Sarah
    Gebauer, Florian
    Vashist, Yogesh K.
    Sauter, Guido
    Pantel, Klaus
    Izbicki, Jakob R.
    Bockhorn, Maximilian
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (02) : 396 - 405
  • [4] ALCAM (CD166) is a surface marker for early murine cardiomyocytes
    Hirata, Hirokazu
    Murakami, Yoshinobu
    Miyamoto, Yoshiaki
    Tosaka, Mako
    Inoue, Kayoko
    Nagahashi, Ayako
    Jakt, Lars Martin
    Asahara, Takayuki
    Iwata, Hiroo
    Sawa, Yoshiki
    Kawamata, Shin
    CELLS TISSUES ORGANS, 2006, 184 (3-4) : 172 - 180
  • [5] ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients
    Tachezy, Michael
    Zander, Hilke
    Marx, Andreas H.
    Gebauer, Florian
    Rawnaq, Tamina
    Kaifi, Jussuf T.
    Sauter, Guido
    Izbicki, Jakob R.
    Bockhorn, Maximilian
    JOURNAL OF SURGICAL RESEARCH, 2011, 170 (02) : 226 - 232
  • [6] EXPRESSION PATTERN OF THE ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE ALCAM/CD166 AS A DIAGNOSTIC AND PROGNOSTIC MARKER IN ENDOMETRIAL CANCER
    Briesel, J.
    Doeleke, F.
    Milde-Langosch, K.
    Sajin, M.
    Bamberger, A. M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4030 - 4030
  • [7] CD166/ALCAM Expression Is Characteristic of Tumorigenicity and Invasive and Migratory Activities of Pancreatic Cancer Cells
    Fujiwara, Kenji
    Ohuchida, Kenoki
    Sada, Masafumi
    Horioka, Kohei
    Ulrich, Charles D., III
    Shindo, Koji
    Ohtsuka, Takao
    Takahata, Shunichi
    Mizumoto, Kazuhiro
    Oda, Yoshinao
    Tanaka, Masao
    PLOS ONE, 2014, 9 (09):
  • [8] Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
    Donizy, Piotr
    Zietek, Marcin
    Halon, Agnieszka
    Leskiewicz, Marek
    Kozyra, Cyprian
    Matkowski, Rafal
    DIAGNOSTIC PATHOLOGY, 2015, 10
  • [9] Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
    Piotr Donizy
    Marcin Zietek
    Agnieszka Halon
    Marek Leskiewicz
    Cyprian Kozyra
    Rafal Matkowski
    Diagnostic Pathology, 10
  • [10] Activated leukocyte cell adhesion molecule (ALCAM/CD166) is an important clinical and prognostic indicator in pancreatic cancer
    Yang, Y. M.
    Sanders, A. J.
    Dong, X.
    Cui, Y.
    Hao, C.
    Ji, J.
    Jiang, W. G.
    BRITISH JOURNAL OF SURGERY, 2021, 108 : V5 - V5
12345